The global nanomedicine market is being aided by the increasing government support and funding, along with the growing requirements of certain therapies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is further being driven by the growing research and investments in novel drug delivery systems. Thus, the market is projected to grow at a CAGR of 11.6% during the forecast period of 2023-2028 to attain a value of nearly USD 391.5 billion by 2026.
The increase in the demand for nanomedicines can be attributed to the rapidly increasing applications of nanomaterials like nanocapsules as well as nanotubes in drug delivery systems. The demand for nanomedicines is further aided by the increase in the incidences of cancer and cardiovascular diseases, leading to the growth of public and private investments in nanomedicine research and advancements in biodegradable nanoparticles. The cost-effectiveness and fewer side-effects of these therapies are also major drivers of the nanomedicine industry growth.
Due to substantial government spending on nanomedicine research in the United States, the North American nanomedicine industry is expected to be one of the leading markets for nanomedicine in the forecast period of 2023-2028. The increased availability of patented nanomedicine items is credited with the region's growth. In addition to a well-developed healthcare infrastructure and a significant incidence of cancer, nanomedicine is easily accessible in this region, which has aided the market growth further.
The large geriatric population in the Asia Pacific is witnessing high incidence rates of cancer and cardiovascular diseases, which is expected to boost the nanomedicine market in the region. The regional market is expected to be one of the fastest growing markets for nanomedicine. The market growth in the Asia Pacific is expected to be aided by the increase in research grants to tackle life-threatening diseases, with countries like China and Japan leading the way.
Nanomedicine is a segment of nanotechnology that is used to diagnose, treat, monitor, and regulate biological systems. It improves medicine delivery by manipulating materials at the nanoscale. As a result, nanomedicine has aided in the treatment of a variety of illnesses. Nanomedicine is still in its infancy, with numerous items under development. Nanobiotix has identified 230 nanomedicine products that are either marked or in the trial phase. Out of the 230 products, 49 are in the market, and 122 are in the clinical trial phases, either in Phase II or Phase III trials.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on product type, the market can be segmented into:
By application, the market is categorised into:
On the basis of nanomolecule type, the industry is categorised into:
The major regional markets of nanomedicine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Currently, the healthcare sector is one of the most important areas where nanotechnology has made significant progress in the detection and treatment of chronic diseases such as cancer, heart disease, and other disorders. Firms researching patch technologies have attracted significant financing as healthcare companies focus on transdermal insulin administration as the industry's emphasis is moving toward transdermal medication delivery. Further, the tailored medication delivery method is being emphasised heavily in order to reduce the risk of side effects. Bypassing the body's defence mechanisms, this method provides reachability with increased efficacy and minimum degradation. Such technological developments and investments are likely to propel the growth of the market in the coming years.
The report gives a detailed analysis of the following key players in the global nanomedicine market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product Type||
|Breakup by Type||
|Breakup by Modality||
|Breakup by Indications||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Nanomedicine Market Overview
3.1 Global Nanomedicine Market Historical Value (2016-2022)
3.2 Global Nanomedicine Market Forecast Value (2023-2031)
4 Global Nanomedicine Market Landscape
4.1 Global Nanomedicine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Nanomedicine Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Modality
4.2.3 Analysis by Indications
5 Global Nanomedicine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Nanomedicine Market Segmentation
6.1 Global Nanomedicine Market by Product Type
6.1.1 Market Overview
6.1.3 Regenerative Medicine
6.2 Global Nanomedicine Market by Type
6.2.1 Market Overview
126.96.36.199 Gold Nanoparticles
188.8.131.52 Iron Oxide Nanoparticles
184.108.40.206 Hydrogel Nanoparticles
6.2.3 Nano shells
6.2.4 Nano Devices
6.3 Global Nanomedicine Market by Modality
6.3.1 Market Overview
6.4 Global Nanomedicine Market by Indications
6.4.1 Market Overview
6.4.2 Drug Delivery
6.4.3 Diagnostic Imaging
6.4.4 Tissue Regeneration
6.4.5 Infectious Disease
6.4.7 Neurological disease
6.5 Global Nanomedicine s Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Nanomedicine Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Nanomedicine Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Nanomedicine Market
9.1 Market Share by Country
10 Latin America Nanomedicine Market
10.1 Market Share by Country
11 Middle East and Africa Nanomedicine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 Invitae Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 General Electric Company
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Leadiant Biosciences, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Johnson & Johnson Services, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Merck Sharp & Dohme Corp.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 Nanosphere Health Sciences, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Celgene Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12 Gilead Sciences, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 Amgen Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14 Bristol-Myers Squibb Company
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.15 Abbvie Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.16 Novartis AG
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.17 F. Hoffmann-La Roche Ltd
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.18 Luminex Corporation
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
18 Global Nanomedicine Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is projected to grow at a CAGR of 11.6% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach nearly USD 391.5 billion by 2026.
The major drivers of the industry, such as emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support and funding, growth in the need for therapies with fewer side effects, and cost-effectiveness of therapies, are expected to aid the market growth.
The key market trends guiding the growth of the industry include out-licensing of nanodrugs and growth of the healthcare facilities.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading product types of nanomedicine in the industry are therapeutics, regenerative medicine, in-vitro diagnostics, in-vivo diagnostics, and vaccines.
The major application segment in the market are clinical oncology, infectious diseases, clinical cardiology, and orthopaedics, among others.
The significant nanomolecule types in the industry are nanoparticles and quantum dots, nanoshells, nanotubes, and nanodevices.
The major players in the industry are Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., Ablynx N.V., AMAG Pharmaceuticals, Inc., and Celgene Corporation, among others.
The global nanomedicine market was driven by the emerging technologies for drug delivery. Aided by the growth in research and investments in novel drug delivery systems, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 11.6%. The market is projected to reach USD 391.5 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product type, the nanomedicine industry can be segmented broadly into therapeutics, regenerative medicine, in-vitro diagnostics, in-vivo diagnostics, and vaccines. By application, the market is divided into clinical oncology, infectious diseases, clinical cardiology, and orthopaedics, among others. On the basis of nanomolecule type, the industry is categorised into nanoparticles and quantum dots, nanoshells, nanotubes, and nanodevices. The major regional markets for nanomedicine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., Ablynx N.V., AMAG Pharmaceuticals, Inc., and Celgene Corporation, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.